Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1016/j.antiviral.2022.105271 http://scihub22266oqcxt.onion/10.1016/j.antiviral.2022.105271 35240221!8882475!35240221     free     free     free Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Antiviral+Res 2022 ; 199 (ä): 105271 Nephropedia Template TP {{tp|p=35240221|t=2022. ACE2-Fc fusion protein overcomes viral escape by potently neutralizing SARS-CoV-2 variants of concern |pdf=|usr=}}{{35240221}} gab.com Text ACE2-Fc fusion protein overcomes viral escape by potently neutralizing SARS-CoV-2 variants of concern JO: Antiviral Res http://www.kidney.de/pget.php?&tw=1&pmid=35240221 #FOAvip COVID-19, an infectious disease caused by the SARS-CoV-2 virus, emerged globally in early 2020 and has remained a serious public health issue. To date, although several preventative vaccines have been approved by FDA and EMA, vaccinated individuals increasingly suffer from breakthrough infections. Therapeutic antibodies may provide an alternative strategy to neutralize viral infection and treat serious cases; however, the clinical data and our experiments show that some FDA-approved monoclonal antibodies lose function against COVID-19 variants such as Omicron. Therefore, in this study, we present a novel therapeutic agent, SI-F019, an ACE2-Fc fusion protein whose neutralization efficiency is not compromised, but actually strengthened, by the mutations of dominant variants including Omicron. Comprehensive biophysical analyses revealed the mechanism of increased inhibition to be enhanced interaction of SI-F019 with all the tested spike variants, in contrast to monoclonal antibodies which tended to show weaker binding to some variants. The results imply that SI-F019 may be a broadly useful agent for treatment of COVID-19. Twit Text FOAVip ACE2-Fc fusion protein overcomes viral escape by potently neutralizing SARS-CoV-2 variants of concern ????Antiviral Res http://www.kidney.de/pget.php?&tw=1&pmid=35240221 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=35240221 #FOAvip English Wikipedia <ref>{{Cite pmid|35240221}}</ref> ACE2-Fc fusion protein overcomes viral escape by potently neutralizing SARS-CoV-2 variants of concern #MMPMID35240221 Tsai TI; Khalili JS; Gilchrist M; Waight AB; Cohen D; Zhuo S; Zhang Y; Ding M; Zhu H; Mak AN; Zhu Y; Goulet DR Antiviral Res 2022[Mar]; 199 (ä): 105271 PMID35240221show ga COVID-19, an infectious disease caused by the SARS-CoV-2 virus, emerged globally in early 2020 and has remained a serious public health issue. To date, although several preventative vaccines have been approved by FDA and EMA, vaccinated individuals increasingly suffer from breakthrough infections. Therapeutic antibodies may provide an alternative strategy to neutralize viral infection and treat serious cases; however, the clinical data and our experiments show that some FDA-approved monoclonal antibodies lose function against COVID-19 variants such as Omicron. Therefore, in this study, we present a novel therapeutic agent, SI-F019, an ACE2-Fc fusion protein whose neutralization efficiency is not compromised, but actually strengthened, by the mutations of dominant variants including Omicron. Comprehensive biophysical analyses revealed the mechanism of increased inhibition to be enhanced interaction of SI-F019 with all the tested spike variants, in contrast to monoclonal antibodies which tended to show weaker binding to some variants. The results imply that SI-F019 may be a broadly useful agent for treatment of COVID-19. |*COVID-19 Drug Treatment[MESH] |*SARS-CoV-2/genetics[MESH] |Angiotensin-Converting Enzyme 2[MESH] |Antibodies, Neutralizing[MESH] |Antibodies, Viral/therapeutic use[MESH] |Humans[MESH]ACE2-Fc fusion protein overcomes viral escape by potently neutralizing(epmc).pdf DeepDyve Pubget Overpricing